论文部分内容阅读
目的观察依达拉奉联合丹红注射液治疗缺血性脑卒中的临床疗效。方法 108例缺血性脑卒中患者,随机分为对照组和观察组,每组54例。对照组在基础治疗上予丹红注射液静脉滴注治疗;观察组在对照组治疗基础上加依达拉奉注射液静脉滴注。对比两组治疗效果。结果治疗后两组的神经功能缺损评分与治疗前比较均明显降低,差异有统计学意义(P<0.01),治疗后两组组间比较,观察组(9.15±3.98)分明显优于对照组(14.20±4.36)分,差异有统计学意义(P<0.05);两组的总有效率比较,观察组94.4%明显优于对照组79.6%(P<0.05)。结论依达拉奉联合丹红注射液由于其良好的药理作用,治疗缺血性脑卒中取得显著的疗效。
Objective To observe the clinical efficacy of edaravone combined with Danhong injection in the treatment of ischemic stroke. Methods 108 cases of ischemic stroke patients were randomly divided into control group and observation group, 54 cases in each group. The control group was treated with intravenous infusion of Danhong injection on the basis of treatment. The observation group received intravenous infusion of edaravone injection on the basis of the control group. Compare the two groups treatment effect. Results After treatment, the scores of neurological deficit in both groups were significantly lower than those before treatment (P <0.01). After treatment, the score of the observation group (9.15 ± 3.98) was significantly better than that of the control group (14.20 ± 4.36) points, the difference was statistically significant (P <0.05). The total effective rate of the two groups was significantly higher than that of the control group (94.4% vs 79.6%, P <0.05). Conclusion Edaravone combined with Danhong injection has achieved significant therapeutic effect on ischemic stroke due to its good pharmacological effects.